PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bfgLink to Publisher's site
 
From:
Published online 2011 January 21. doi: 10.1093/bfgp/elr002

Table 2:

AML-associated oncofusion proteins

Chromosomal translocationOncofusion proteinOccurrence (% of AML)PrognosisFAB
t(8;21)(q22;q22)AML1–ETO5–12FavorableM2
t(15;17)(q22;q21)PML–RARα6–15FavorableM3
inv(16)(p13q22)CBFβ–MYH113–10FavorableM4
der(11q23)MLL-fusions5–8VariableM4/M5
t(9;22)(q34;q11)BCR–ABL11–2AdverseM1/M2
t(6;9)(p22;q34)DEK–NUP214<1AdverseM2/M4
t(1;22)(p13;q13)RBM15–MKL1<1IntermediateM7
t(8;16)(p11;p13)MYST3–CREBBP<1AdverseM4/M5
t(7;11)(p15;p15)NUP98–HOXA9<1IntermediateM2/M4
t(12;22)(p12;q11)MN1–TEL<1VariableM4/M7
inv(3)(q21;q26)RPN1–EVI1<1AdverseM1/M2/M4/M6/M7
t(16;21)(p11;q22)FUS–ERG<1AdverseM1/M2/M4/M5/M7